

## **CMC Biopharmaceuticals A/S appoints Dr. Diana Morgan as Chief Business Officer**

**Copenhagen, Denmark; March 10, 2006** – CMC Biopharmaceuticals A/S (CMC), a leading provider of contract bio-manufacturing services to the biopharmaceutical industry, has appointed Diana Morgan, PhD as Chief Business Officer.

Mads Laustsen, Chief Executive Officer, commented “I am pleased to welcome Diana to the CMC team. Her proven leadership and extensive experience of the biotechnology industry globally will enable CMC to continue to grow its business and build on the reputation it is rapidly acquiring as a leading high-quality manufacturer within the biotechnology industry”.

Following a successful career in cancer research in the fields of cell biology and virology, Diana moved into the biotechnology sector and has spent the last 11 years with BioReliance, a global biosafety testing company. She joined BioReliance as Study Director in the European Biosafety Division before moving into sales and marketing as European Director of Sales. Her success in that role led to her appointment as Vice President of Global Sales and Marketing in 2003. Most recently at BioReliance, now part of the Invitrogen Corporation, her role as Global Leader of Manufacturing comprised overall responsibility for business development and operations within the manufacturing division.

Diana Morgan commented “I am delighted to be joining CMC a company that I have been following over the years as they have become an increasingly important player in the bio-manufacturing sector.”

### **About CMC Biopharmaceuticals A/S**

Based in Copenhagen, Denmark, CMC is a contract development and manufacturing organization with sales offices located in the UK and the US. CMC specialises in the provision of tailored services to the global biopharmaceutical industry for process and analytical development as well as the scale-up and cGMP manufacture of protein-based therapeutics. The company’s purpose built facility has fully segregated microbial fermentation and mammalian cell culture suites and offers both stirred tank and perfusion production processes. Services offered include a comprehensive range of process development activities and cGMP manufacturing for clinical and market supply.

Further information is available from:

Chief Executive Officer, Mads Laustsen. Phone: +45 3954 8401.

Email: [ml@cmcbio.com](mailto:ml@cmcbio.com)

Web: [www.cmcbio.com](http://www.cmcbio.com)